Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: A randomized controlled trial

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 1017-1024

  Kuo, Chao Hung ^a,b,c   Hu, Huang Ming ^a   Kuo, Fu Chen ^d   Hsu, Ping I ^e   Chen, Angela ^f   Yu, Fang Jung ^b   Tsai, Pei Yun ^a   Wu, I Chen ^b   Wang, Sheng Wen ^b   Li, Chia Jung ^b   Weng, Bi Chuang ^b   Chang, Lin Li ^g   Jan, Chang Ming ^b,c   Wang, Wen Ming ^b,c   Wu, Deng Chyang ^b,c,f  

^a KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

CYP2C19; Fluoroquinolones; H. pylori

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; CYTOCHROME P450 2C19; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPY; ERADICATION THERAPY; FEMALE; GENETIC ANALYSIS; GENOTYPE; HEADACHE; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STOMACH BIOPSY; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UREA BREATH TEST; VOMITING;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; SALVAGE THERAPY; TETRACYCLINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64649086513     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp034     Document Type: Article

References (49)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-9.
2. Teh BH, Lin JT, Pan WH et al. Seroprevalence and associated risk factors of Helicobacter pylori infection in Taiwan. Anticancer Res 1994; 14: 1389-92.
3. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
4. Bytzer P, O'Morain C. Treatment of Helicobacter pylori. Helicobacter 2005; 10 Suppl 1: 40-6.
5. Huang AH, Sheu BS, Yang HB et al. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc 2000; 99: 704-9.
6. Zanten SJ, Bradette M, Farley A et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-95.
7. Sheu BS, Wu JJ, Lo CY et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 1669-75.
8. Bazzoli F, Pozzato P, Rokkas T. Helicobacter pylori: The challenge in therapy. Helicobacter 2002; 7 Suppl 1: 43-9.
9. Georgopoulos SD, Ladas SD, Karatapanis S et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002; 16: 569-75.
10. Peitz U, Sulliga M, Wolle K et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: Impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002; 16: 315-24.
11. Dupas JL. [First line therapy for Helicobacter pylori eradication in France]. Gastroenterol Clin Biol 2003; 27: 467-72.
12. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997; 11 Suppl 1: 43-53.
13. Ducons JA, Santolaria S, Guirao R et al. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999; 13: 775-80.
14. Megraud F, Lamouliatte H. Review article: The treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1333-43.
15. Goodwin CS, Marshall BJ, Blincow ED et al. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: Clinical and in vitro studies. J Clin Pathol 1988; 41: 207-10.
16. Kim JG. [Treatment of Helicobacter pylori infection]. Korean J Gastroenterol 2005; 46: 172-80.
17. Gisbert JP, Pajares JM. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-57.
18. Wong WM, Gu Q, Chu KM et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 421-7.
19. Gerrits MM, van Vliet AH, Kuipers EJ et al. Helicobacter pylori and antimicrobial resistance: Molecular mechanisms and clinical implications. Lancet Infect Dis 2006; 6: 699-709.
20. Croom KF, Goa KL. Levofloxacin: A review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63: 2769-802.
21. Sanchez JE, Saenz NG, Rincon MR et al. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/ dalfopristin and new quinolones. J Antimicrob Chemother 2000; 46: 283-5.
22. Tanaka M, Isogai E, Isogai H et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002; 49: 1039-40.
23. Giannini EG, Bilardi C, Dulbecco P et al. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther 2006; 23: 281-7.
24. Gatta L, Zullo A, Perna F et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45-9.
25. Coelho LG, Moretzsohn LD, Vieira WL et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: A pilot study. Aliment Pharmacol Ther 2005; 21: 783-7.
26. Gisbert JP, Castro-Fernandez M, Bermejo F et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006; 101: 243-7.
27. Spengler G, Molnar A, Klausz G et al. Inhibitory action of a new proton pump inhibitor, trifluoromethyl ketone derivative, against the motility of clarithromycin-susceptible and -resistant Helicobacter pylori. Int J Antimicrob Agents 2004; 23: 631-3.
28. Figura N, Crabtree JE, Dattilo M. In-vitro activity of lansoprazole against Helicobacter pylori. J Antimicrob Chemother 1997; 39: 585-90.
29. Furuta T, Shirai N, Sugimoto M et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-67.
30. Wu IC, Ke HL, Lo YC et al. Evaluation of a newly developed office-based stool test for detecting Helicobacter pylori: An extensive pilot study. Hepatogastroenterology 2003; 50: 1761-5.
31. Hsu PI, Hwang IR, Cittelly D et al. Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol 2002; 97: 2231-8.
32. De Morais SM, Wilkinson GR, Blaisdell J et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
33. de Morais SM, Wilkinson GR, Blaisdell J et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22.
34. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-4.
35. Huang JQ, Hunt RH. Treatment after failure: The problem of 'non-responders'. Gut 1999; 45 Suppl 1: I40-4.
36. Matsuzaki K, Koyama H, Chiba A et al. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates]. Jpn J Antibiot 1999; 52: 571-84.
37. Cammarota G, Martino A, Pirozzi G et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004; 19: 789-95.
38. Best LM, Haldane DJ, Bezanson GS et al. Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. Can J Gastroenterol 1997; 11: 298-300.
39. Cabrita J, Oleastro M, Matos R et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-31.
40. Zullo A, Hassan C, Lorenzetti R et al. Helicobacter pylori eradication: Do we have another ace up our sleeve? Dig Liver Dis 2001; 33: 805-6.
41. Watanabe Y, Aoyama N, Shirasaka D et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003; 35: 711-5.
42. Matsumoto Y, Miki I, Aoyama N et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005; 37: 821-5.
43. Fujimura S, Kato S, Iinuma K et al. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol 2004; 53: 1019-22.
44. Kim JM, Kim JS, Kim N et al. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006; 28: 6-13.
45. Marzio L, Coraggio D, Capodicasa S et al. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006; 11: 237-42.
46. Cheng HC, Chang WL, Chen WY et al. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter 2007; 12: 359-63.
47. Hassan-Alin M, Andersson T, Bredberg E et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56: 665-70.
48. Dent J. Review article: Pharmacology of esomeprazole and comparisons with omeprazole. Aliment Pharmacol Ther 2003; 17 Suppl 1: 5-9.
49. Saad RJ, Schoenfeld P, Kim HM et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: A meta-analysis. Am J Gastroenterol 2006; 101: 488-96.